Marketing-Börse PLUS - Fachbeiträge zu Marketing und Digitalisierung
print logo

Global Melanoma Cancer Diagnostics Market Value is Expected to Increase to US$ 853.5 Million by 2022

The global melanoma cancer diagnostics market is projected to grow at a steady CAGR during the forecast period 2017-2027.
MarketsandMarkets™ | 18.08.2017

According to a latest market research by fast-growing market research and consulting firm, the global melanoma cancer diagnostics market is poised to grow at over 7% CAGR and surpass US$ 853.5 million in revenues by 2022. Fact.MR’s report forecasts that North America and Europe will remain the most lucrative markets for melanoma cancer diagnostics market globally. Key takeaways from Fact.MR’s report are,


  • The U.S. melanoma cancer diagnostics market will grow at over 7% CAGR and reach US$ 409.2 Mn by 2022. By test type, BRAF mutation segment will continue to be the leading segment.


Request For Sample Report @  https://www.factmr.com/connectus/sample?flag=S&rep_id=57

  • Germany is one of the largest markets for melanoma cancer diagnostics in Europe. Fact.MR projects the Germany melanoma cancer diagnostics market to grow at 7.4% CAGR through 2022. Hospital associated labs are the largest end-users of melanoma cancer diagnostics in Germany. The market in United Kingdom will grow at a higher rate than Germany, but it will be continue to be smaller in market size.

  • The market will be positive influenced by increasing R&D on cancer diagnosis and management. Increasing prevalence of melanoma and effective immunotherapies are expected to drive growth of the market globally.

  • Although the outlook on the global melanoma cancer diagnostics market is positive, limited funds in emerging countries, combined with challenges surrounding regulatory issues can stymie growth during the forecast period.

  • By test type, BRAF mutation segment will account for a significant share of global revenues. This test type will continue to be used widely in major markets of North America and Europe. The CTC segment, on the other hand, is projected to grow at a higher CAGR than BRAF segment. Immunohistochemistry, another test type, is projected to grow at over 6% CAGR in the global melanoma cancer diagnostics market.


Check Discount @ https://www.factmr.com/connectus/sample?flag=D&rep_id=57

  • The key end-use segments of the global melanoma cancer diagnostics market have been identified as hospital associated labs, cancer research institutes, and independent diagnostic laboratories. Among these, the hospital associated labs end-use segment is the most prominent globally. According to Fact.MR’s research, hospital associated labs will remain the largest end-users for melanoma cancer diagnostics market during the forecast period.

  • Demand is also expected to remain steady from independent diagnostic laboratories segment. In North America, demand from this segment is expected to surpass US$ 100 million by 2022. The trend will also remain strong in Europe, with this segment growing at nearly 8% CAGR during the forecast period.

  • Leading companies profiled in the report include Cancer Genetics, Inc., Myriad Genetics Inc. Abbott Laboratories, Foundation Medicine, Inc., and Pathway Genomics Corporation


Click to View Complete Report @ https://www.factmr.com/report/57/melanoma-cancer-diagnostics-market

About Us

Fact.MR is a fast-growing market research firm that offers the most comprehensive suite of syndicated and customized market research reports. We believe transformative intelligence can educate and inspire businesses to make smarter decisions. We know the limitations of the one-size-fits-all approach; that's why we publish multi-industry global, regional, and country-specific research reports.

Contact Us

Fact.MR

Office: Dublin 2

Suite 9884

27 Upper Pembroke Street,

Dublin 2, Ireland

Tel: +353-1-6111-593

( Dublin 2 )

Email: sales@factmr.com

Web: https://www.factmr.com

Img of MarketsandMarkets™
About the tenderer: MarketsandMarkets™

MarketsandMarkets is the largest market research firm worldwide in terms of annually published premium market research reports.